Abstract:Atherosclerosis is a multi-factorial inflammatory disease with accumulation of lipids and recruitment of leukocytes into the subendothelial space. Due to the consistent inflammation in vessels, a subset of atherosclerotic plaques is even prone to physical disruption or producing thrombosis that triggers acute coronary syndromes (ACS). Cyclooxygenase (COX) and the downstream diverse prostanoids are involved in numerous physiological activities and inflammatory processes. Remarkably, prostanoids are a group of bioactive lipid mediators, and play a series of complicated and even contradictory roles during the progression of atherogenesis. Some, mainly prostacyclin (PGI2) have cardioprotective effects to inhibit the aggravation of atherosclerosis, however, others including prostaglandin E2 (PGE2) and thromboxane A2 (TXA2), increase the risk of cardiovascular thromboembolic events. Therefore, the controversial effects bring about a debate on the use of cyclooxygenase-2 (COX-2) specific and non-specific inhibitors in the prevention from cardiovascular diseases. In addition to reverse cholesterol transport (RCT), high-density lipoprotein (HDL) exerts several beneficial effects on endothelial protection. Moreover, HDL could also regulate the expression of COX-2 and the production of PGI2 in endothelial cells. While as a diverse complex of heterogeneous particle composed of various apolipoproteins, enzymes and lipids, the individual components of HDL, such as apolipoprotein A-I (apoA-I) and sphingosine-1-phosphate (S1P), have distinct effects on COX-2 expression and PGI2 production in endothelial cells. In the present review, we summarize the roles of COX-2 as well as PGI2 in atherosclerosis and atherothrombosis, the controversial vascular effects on prostanoid inhibition by COX-2 inhibitors, and the effects of HDL on the endothelial protection by the upregulation of COX-2 and the release of PGI2 during the progression of atherosclerosis.

Prostaglandin E Receptors As Inflammatory Therapeutic Targets for Atherosclerosis

PROSTAGLANFIN E RECEPTORS AS INFLAMMATORY THERAPEUTIC TARGETS FOR ATHEROSCLEROSIS

Prostaglandin E Receptor Subtype 4 Signaling in the Heart: Role in Ischemia/Reperfusion Injury and Cardiac Hypertrophy.

An Update of Microsomal Prostaglandin E Synthase-1 and PGE2Receptors in Cardiovascular Health and Diseases

Single Hormone or Synthetic Agonist Induces Gs/Gi Coupling Selectivity of EP Receptors Via Distinct Binding Modes and Propagating Paths.

Ligand recognition, unconventional activation, and G protein coupling of the prostaglandin E<sub>2</sub> receptor EP2 subtype

Roles of the prostaglandin E 2 receptors EP subtypes in Alzheimer’s disease

Targeted Disruption of the Prostaglandin E2 E-prostanoid 2 Receptor Exacerbates Vascular Neointimal Formation in Mice.

Purinergic receptors mediate endothelial dysfunction and participate in atherosclerosis

Prostaglandin receptor EP4 in abdominal aortic aneurysms

Cyclooxygenase-2 expression, prostacyclin production and endothelial protection of high-density lipoprotein.

The Latest Progress in E-Prostanoid (EP) Receptor Subtypes EP2 and EP4

Prostanoids receptors signaling in different diseases/cancers progression.

[Prostaglandin(pg) E2 in Regulation of Immunity and Inflammatory Diseases].

Structural Insights into Selective and Dual Antagonism of EP2 and EP4 Prostaglandin Receptors

Antihypertensive Effects of Selective Prostaglandin E-2 Receptor Subtype 1 Targeting

Role of PGE2 in Blood Pressure Regulation

Prostaglandin E Receptors in Regulation of Blood Pressure

Prostaglandin E-2 Receptor Ep4 Contributes to Inflammatory Pain Hypersensitivity

Distinct Roles of Central and Peripheral Prostaglandin E2 and EP Subtypes in Blood Pressure Regulation

Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease